Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888327 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL1666369 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL3697952 | 0.90 | CYP1A2 (0.59) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL1030936 | 0.89 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL6256628 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL889733 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL31146698 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL2065608 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL888202 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 | |
| Methyl Alcohol SCHEMBL6832436 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670523-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | Agilent Technologies, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIV CINCINNATI (US) | 2016-04-14 | — | — | US | disclosed |
| US-9200319-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150140559-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2014194250-A2 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIVERSITY OF CINCINNATI (US) | 2014-12-04 | — | — | WO | disclosed |
| US-8877905-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877905-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| CN-103588839-A | Nucleotides and nucleosides and method for their use in DNA sequencing | LASERGEN INC | 2014-02-19 | — | — | CN | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102264917-A | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | — | 2011-11-30 | — | — | CN | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | ALDH1A1 1889/4885CYP1A2 1691/4885CYP3A4 1181/4885 |
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | DCTD, TYMS, CDA | ALDH1A1 2714/4885CYP1A2 3664/4885CYP3A4 3555/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | ALDH1A1 1889/4885CYP1A2 1691/4885CYP3A4 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.